Reading view
DropoutTS: Sample-Adaptive Dropout for Robust Time Series Forecasting
Decoding ML Decision: An Agentic Reasoning Framework for Large-Scale Ranking System
SEA-Eval: A Benchmark for Evaluating Self-Evolving Agents Beyond Episodic Assessment
Data Difficulty and the Generalization--Extrapolation Tradeoff in LLM Fine-Tuning
Cusp-singularity-enhanced Coriolis effect for sensitive chip-scale gyroscopes
Nature, Published online: 20 May 2026; doi:10.1038/s41586-026-10565-w
By using singularity physics to enable cubic-root scaling of frequency and phase modulations induced by the Coriolis effect to enhance the performance of chip-scale Coriolis vibratory gyroscopes, substantial improvements in signal-to-noise ratio and precision are demonstrated.NDRG2 orchestrates circadian clock stability to suppress tumorigenesis and potentiate oxaliplatin response in colorectal cancer
Oncogene, Published online: 19 May 2026; doi:10.1038/s41388-026-03823-8
NDRG2 orchestrates circadian clock stability to suppress tumorigenesis and potentiate oxaliplatin response in colorectal cancerTransplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease models
An operational target trial emulation framework for causal inference using electronic health record data
npj Digital Medicine, Published online: 04 April 2026; doi:10.1038/s41746-026-02563-z
An operational target trial emulation framework for causal inference using electronic health record dataHoloTrauma 3X Triadic AI Co reasoning for robot assisted emergency maxillofacial reconstruction
npj Digital Medicine, Published online: 04 April 2026; doi:10.1038/s41746-026-02573-x
HoloTrauma 3X Triadic AI Co reasoning for robot assisted emergency maxillofacial reconstructionLifting Unlabeled Internet-level Data for 3D Scene Understanding
The 1000 Chinese Pangenome empowers medical and population genetics
Nature, Published online: 01 April 2026; doi:10.1038/s41586-026-10315-y
Development of the pangenome-informed genome assembly (PIGA) workflow enabled the generation of 1,116 diploid genome assemblies (55 de novo and 1,061 pangenome-informed), representing an extensive resource of medically relevant genic variations.Doxorubicin promotes the production of inflammatory cytokines in tumor-associated macrophages through activating lactate dehydrogenase A
Cell Death Discovery, Published online: 31 March 2026; doi:10.1038/s41420-026-03014-0
Doxorubicin promotes the production of inflammatory cytokines in tumor-associated macrophages through activating lactate dehydrogenase ANew perspectives in immunotherapy for hepatocellular carcinoma: Focusing on resistance mechanism, biomarker, and personalized treatment
Crit Rev Oncol Hematol. 2026 Mar 27;222:105305. doi: 10.1016/j.critrevonc.2026.105305. Online ahead of print.
ABSTRACT
The management of hepatocellular carcinoma (HCC) faces substantial and evolving challenges, driven by its aggressive biology, drug resistance, and the clinical urgency to detect recurrence. The treatment paradigm has undergone a profound transformation, evolving from surgical interventions and molecular targeted agents to the current era dominated by immunotherapy. Immune checkpoint inhibitors, particularly when used in combination with anti-angiogenic drugs or as part of dual-checkpoint blockade regimens, have established a new first-line standard of treatment for advanced HCC, delivering unprecedented survival improvements. Despite this progress, significant obstacles remain, including primary and acquired resistance, variable patient responses, and notably reduced efficacy in specific etiological subgroups. This comprehensive review synthesizes the emerging modalities such as bispecific antibodies, adoptive cell therapies, and innovative rational combinations that integrate systemic immunotherapy with locoregional treatments or novel targeted agents. Furthermore, we delve into the critical search for predictive biomarkers, encompassing liquid biopsy and multi-omics approaches, and dissect the complex cellular and molecular mechanisms underlying therapeutic resistance within the immunosuppressive tumor microenvironment. Finally, we outline future translational directions, emphasizing the expansion of immunotherapy, the development of tailored strategies for therapy-resistant disease, and the imperative move towards a personalized, biomarker-driven treatment framework. This review provides a cohesive overview of the field and charts a roadmap for future research to overcome the current challenges in HCC immunotherapy.
PMID:41905572 | DOI:10.1016/j.critrevonc.2026.105305
Scaling Attention via Feature Sparsity
Targeted therapies in lung cancer: personalizing treatment across the age spectrum
Front Oncol. 2026 Feb 25;16:1743620. doi: 10.3389/fonc.2026.1743620. eCollection 2026.
ABSTRACT
Lung cancer remains the leading cause of cancer-related mortality, yet current precision oncology approaches remain overwhelmingly tumor-centric, guided by genomic alterations and immune biomarkers, while largely neglecting the profound impact of aging biology on treatment response. While emerging evidence suggests that aging biology can modify therapeutic benefit and toxicity, its clinical integration remains uneven and largely investigational. In this review, we explicitly distinguish the chronological aging from biological aging to clarify how host biology modifies therapeutic benefit and toxicity. We synthesize mechanistic, translational, and early clinical evidence, while explicitly noting areas where prospective validation is lacking, to reframe personalization of lung cancer therapy through an age-conscious lens. We summarize data indicating that immunosenescence is associated with T-cell exhaustion, myeloid dominance, and extracellular matrix stiffening, features that may contribute to immune-evasive tumor phenotypes and attenuated responses to immune checkpoint blockade in subsets of patients, while pediatric cases, though rare, illustrate how global precision initiatives like iTHER and ZERO enable cautious adaptation of adult therapies. Moving beyond chronological age, we discuss biological age biomarkers, including PhenoAgeAccel, epigenetic clocks, telomere length, and frailty indices, which outperform traditional metrics in predicting risk, resistance, and toxicity, and propose integrating these tools into trial design, screening, and care planning which show promise for risk stratification and toxicity prediction but are not yet validated for routine treatment selection. Looking forward, we outline investigational strategies at the intersection of geroscience and oncology, including immune engineering, senolytics, microenvironmental modulation, and AI-driven multi-omic modeling. Overall, this review argues that biological age represents a critical but still underdeveloped dimension of precision oncology, and highlights key evidence gaps that must be addressed before age-aware personalization can be implemented in routine lung cancer care.
PMID:41821888 | PMC:PMC12975599 | DOI:10.3389/fonc.2026.1743620
Regulatory mechanisms of ALKBH5/CIITA axis in the synergistic modulation of hepatocellular carcinoma radiotherapy and immunotherapy
Genes Immun. 2026 Mar 10. doi: 10.1038/s41435-026-00382-6. Online ahead of print.
ABSTRACT
The prognosis for hepatocellular carcinoma remains grim. Combining radiotherapy with immune checkpoint blockade (ICB) has shown potential to enhance therapeutic outcomes, yet there is a pressing need for further advancements. Our previous research demonstrated that this combined approach suppresses ALKBH5 gene expression and increases m6A modification levels in hepatocellular carcinoma tissues. High-throughput sequencing and detailed molecular analysis revealed that inhibiting ALKBH5 amplifies CIITA m6A modifications post-therapy. This modulation triggers MHC II molecule expression in tumors, facilitating the presentation of tumor-associated antigens to CD4 + T lymphocytes and the recruitment of CD8 + T cells for an anti-tumor immune response. Building on these findings, we engineered a CIITA vector with a specific site mutation to confirm that the regulation of CIITA by the combined radiotherapy and immunotherapy is mediated through m6A methylation. Consequently, we established a comprehensive network involving ALKBH5, CIITA, MHC II, and CD4+ and CD8 + T cells. To elucidate the role and underlying molecular mechanisms of this combined therapy in reshaping the tumor immune microenvironment for hepatocellular carcinoma, we employed multi-omics approaches across in vitro, animal model, and clinical multi-dimensional studies, offering novel insights for enhancing treatment efficacy.
PMID:41807814 | DOI:10.1038/s41435-026-00382-6